Molecular therapy for gastric cancer

Several agents that target specific molecules have been investigated for the treatment of gastric cancer in many preclinical and clinical studies. Anti-HER2 antibody, when combined with classical cytotoxic agents, has been shown to confer a significant survival benefit in patients with HER2-positive gastric cancer. This is the only targeted drug that has been shown to be successful for the treatment of gastric cancer. We need to determine specific targets for regulating gastric cancer cells by translational research, develop precise diagnostic procedures for personalized medicine, and identify candidate drugs for gastric cancer.